NCT07351825 CMR Prognostic Markers in Ischemic Heart Disease
| NCT ID | NCT07351825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Condition | Ischemic Heart Disease (IHD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2009-01 |
| Primary Completion | 2035-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2009-01 with a primary completion date of 2035-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Accurate risk stratification is essential for guiding clinical management and improving long-term outcomes in patients with ischemic myocardial injury. Cardiovascular magnetic resonance (CMR) imaging provides comprehensive assessment of myocardial structure, function, and tissue characteristics, enabling detailed evaluation of ischemic injury and its consequences. This multicenter, retrospective observational study aims to investigate the prognostic value of multiparametric CMR-derived imaging markers in patients with ischemic heart disease who underwent clinically indicated CMR examinations. Imaging parameters of interest include late gadolinium enhancement (LGE), infarct size, microvascular obstruction (MVO), left ventricular and left atrial strain, and native T1 and T2 mapping values. Long-term clinical outcomes will be obtained from existing medical records. The primary outcome is major adverse cardiovascular and cerebrovascular events (MACCE), and secondary outcome is cardiovascular death. This study seeks to clarify the role of CMR in long-term risk stratification of patients with ischemic heart disease.
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥18 years of age). 2. Patients with ischemic heart disease, including prior or recent myocardial infarction, who underwent clinically indicated cardiac magnetic resonance (CMR) imaging. 3. Availability of analyzable CMR images, including but not limited to cine imaging, late gadolinium enhancement (LGE), and parametric mapping sequences (T1 and/or T2 mapping), as applicable. 4. Availability of baseline clinical data and longitudinal follow-up information. Exclusion Criteria: 1. Poor image quality or incomplete CMR data precluding quantitative analysis. 2. Presence of other severe comorbid conditions expected to significantly affect survival or clinical outcomes. 3. Missing key clinical outcome data during follow-up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07351825 clinical trial?
This trial is open to participants of all sexes, studying Ischemic Heart Disease (IHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07351825 currently recruiting?
Yes, NCT07351825 is actively recruiting participants. Contact the research team at tianzx826@163.com for enrollment information.
Where is the NCT07351825 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07351825 clinical trial?
NCT07351825 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 1,000 participants.